CoChat

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.

Antonia, Scott Joseph, Gettinger, Scott N., Chow, Laura Quan Man, Juergens, Rosalyn A., Borghaei, Hossein, Shen, Yun, Harbison, Christopher, Chen, Allen C., Ready, Neal, Rizvi, Naiyer A. · 2014 · Journal of Clinical Oncology
Cited by 125

The DOI matches its Crossref record.

Abstract

8023 Background: Nivolumab, a fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, and ipilimumab, an IgG1 CTLA-4 checkpoint receptor blocking antibody, have shown activity in advanced NSCLC; clinical data in melanoma showed improved responses and a manageable safety profile when combined. We report interim results from a phase I study evaluating first-line nivolumab + ipilimumab (N+I) in advanced NSCLC patients (pts). Methods: Chemotherapy-naive pts (n=46) with squamous (sq) or non-sq NSCLC received the 3 + 1 mg/kg or 1 + 3 mg/kg combination dose IV Q3W for 4 cycles followed by nivolumab 3 mg/kg IV Q2W until progression/unacceptable toxicity. Objective response rate (ORR; RECIST 1.1) was evaluated overall and by baseline tumor PD-L1 status (Dako immunohistochemistry assay). After an amendment, a 1 + 1 mg/kg cohort was added (n=30, data immature at Dec 2013 analysis). Results: In the 4 cohorts with ≥4 months follow up, any-grade treatment-related adverse events (managed with protocol algorithms) were reported in 39 pts (85%; grade 3–4 in 22 pts [48%]) and led to discontinuation in 16 pts. Treatment-related deaths (n=3) were due to respiratory failure, bronchopulmonary hemorrhage and toxic epidermal necrolysis. Responses occurred in all 4 cohorts (Table); overall ORRb was 22% (median duration of response [mDOR] not reached [NR]) and stable disease (SD) 33% (range 13 – 34.1+ wks); 2 pts exhibited unconventional “immune related” responses. In 29 evaluable tumor samples from the study, ORR did not correlate with PD-L1 status. Conclusions: These interim data in pts with advanced NSCLC suggest that a nivolumab + ipilimumab immunotherapy regimen is feasible and demonstrates antitumor activity in both PD-L1+ and PD-L1– pts. Safety will be further assessed at the 1 + 1 mg/kg dose. The recommended combination dose for phase II/III evaluation has not been determined. Clinical trial information: NCT01454102. N1 + I3 Sq N1 + I3 Non-sq N3 + I1 Sq N3 + I1 Non-sq N 7 15 8 16 ORR,a n (%) 1 (14) 1 (7) 2 (25) 2 (13) ORR,b n (%) 1 (14) 2 (13) 3 (38) 4 (25) 3 (14) 7 (29) SD, n (%) 2 (29) 6 (40) 4 (50) 3 (19) mDOR (Kaplan-Meier),a wk (range) NR (9+) NR (21+) 17 (12, 21) NR (24+, 25+) Ongoing responders,a n (%) 1 (100) 1 (100) 0 2 (100) a Confirmed OR only. b Confirmed + unconfirmed OR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.32.15_suppl.8023

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 125

Metadata

Authors
Antonia, S. J., Gettinger, S. N., Chow, L. Q. M., Juergens, R. A., Borghaei, H., Shen, Y., Harbison, C., Chen, A. C., Ready, N., & Rizvi, N. A.
Venue
Journal of Clinical Oncology
Published
2014-05-20
Volume
32
Issue
15_suppl
Pages
8023-8023
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2526642223
Cited by
125
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. https://app.cochat.ai/papers/10.1200/jco.2014.32.15_suppl.8023
The paper
Antonia, S. J., Gettinger, S. N., Chow, L. Q. M., Juergens, R. A., Borghaei, H., Shen, Y., Harbison, C., Chen, A. C., Ready, N., & Rizvi, N. A. (2014). Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.32.15_suppl.8023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.